D3Sciences
Private Company
Funding information not available
Overview
D3Sciences is tackling a fundamental bottleneck in oncology: the inadequacy of standard biopsy samples for advanced diagnostic and molecular testing. The company is developing tools designed to obtain larger, more representative tissue samples during image-guided biopsies, thereby enabling comprehensive tumor profiling and personalized treatment planning. By bridging the gap between diagnostic capabilities and sampling techniques, D3Sciences seeks to improve diagnostic accuracy, therapy specificity, and accelerate cancer research. Its value proposition centers on empowering the clinical team—oncologists, radiologists, and pathologists—with better tissue to 'do more' for patients.
Technology Platform
Platform focused on developing tools to improve tissue sampling during image-guided biopsies, aiming to retrieve larger, higher-quality tissue cores for comprehensive cancer diagnosis and molecular profiling.
Opportunities
Risk Factors
Competitive Landscape
D3Sciences competes in the biopsy device market against large medtech incumbents like Becton Dickinson and Medtronic. Its differentiation is a focused claim of superior tissue yield. It also faces indirect competition from technological alternatives, such as improvements in liquid biopsy, which aim to reduce reliance on tissue sampling altogether.